Cancer is as complex as the people it affects. Decoding those differences at a genomic level is key to precision oncology. Psomagen was delighted to work with Agilent Technologies and SeqOne on this recent white paper. In it, we assisted in testing the capability of Agilent’s SureSelect Cancer CGP assay and implemented minor changes to the CGP protocol to enable low-pass whole-genome sequencing (WGS).
The low-pass WGS data was used to assess homologous recombination deficiency (HRD) status in solid tumor samples. HRD status is an important biomarker in cancer research and treatment, and can indicate how a patient would respond to PARP inhibitors.
The SureSelect Cancer CGP assay includes a DNA panel of 679 genes and an RNA panel of 80 genes. This assay can detect:
-
Single-nucleotide variants
-
Copy number variants
-
Insertions/deletions
-
Translocations
-
Immuno-oncology biomarkers
-
Tumor mutational burden
-
Microsatellite instability
-
RNA gene fusions
As part of this assessment, Agilent added low-pass whole-genome sequencing to the existing CGP assay. The workflow was then tested on samples with known HRD status and negative controls. This test used a range of reference materials, including Agilent Human Reference DNA and Seraseq FFPE HRD controls (High-Pos RM, Low-Pos RM, and Negative RM), ensuring accuracy and reliability across different sample types.
Psomagen provided sample processing and data generation for the CGP HRD assay, providing essential data for downstream HRD analysis. This genomic data then went through the SeqOne SomaHRD bioinformatic pipeline. Results were overwhelmingly accurate and reproducible. Learn more when you download the full white paper at the link below.
About Psomagen
Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
Psomagen Contact
Abhilasha Cheruku
Genomics Services Product Manager
acheruku@psomagen.com
About Agilent
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. For more information, visit agilent.com.
About SeqOne
SeqOne Genomics is a leading provider of genomic data analysis solutions, offering fast, accurate, and scalable genomic analysis for healthcare providers. With a specialized focus on oncology and rare diseases, SeqOne’s technology equips healthcare providers with the insights needed to deliver personalized patient care and advance diagnostic accuracy in genomic medicine. For more information, visit seqone.com.
